Skip to main content

Advertisement

SpringerLink
Log in

Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP) are recognized complications of chronic lymphocytic leukemia (CLL) that can be life-threatening if not managed appropriately. Conventional therapies for these autoimmune disorders, such as corticosteroids, splenectomy, and immunosuppressive agents, may not induce complete resolution in all patients, and relapses are common. In recent years, monoclonal antibodies such as alemtuzumab and rituximab, already used successfully for the management of lymphoproliferative disorders, have been shown to be effective in the treatment of a range of autoimmune disorders. The potent antitumor activity of alemtuzumab, in combination with its profound immunosuppressive activity, prompted investigation of its use in patients with severe CLL-related AIHA and ITP. Results from a range of reports confirm the efficacy of alemtuzumab for the treatment of severe, CLL-related autoimmune cytopenias that have failed to respond to conventional therapies and may even be rituximab-refractory.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998, 25:80–97.

    PubMed  CAS  Google Scholar 

  2. Mauro FR, Foa R, Cerretti R, et al.: Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood 2000, 95:2786–2792.

    PubMed  CAS  Google Scholar 

  3. Hamblin T: Autoimmune disease and its management in chronic lymphocytic leukemia. In Chronic Lymphoid Leukemias. Edited by Cheson BD. New York: Marcel Dekker; 2001:435–458.

    Google Scholar 

  4. Hamblin TJ: Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006, 33:230–239.

    Article  PubMed  CAS  Google Scholar 

  5. Valent P, Lechner K: Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review. Wien Klin Wochenschr 2008, 120:136–151.

    Article  PubMed  Google Scholar 

  6. Robak T: Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004, 72:79–88.

    Article  PubMed  CAS  Google Scholar 

  7. Rawstron AC, Green MJ, Kuzmicki A, et al.: Monoclonal B lymphocytes with the characteristics of “indolent” chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002, 100:635–639.

    Article  PubMed  CAS  Google Scholar 

  8. Mittal S, Blaylock MG, Culligan DJ, et al.: A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura. Haematologica 2008, 93:151–152.

    Article  PubMed  Google Scholar 

  9. Stasi R, Del Poeta G, Stipa E, et al.: Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007, 110:2924–2930.

    Article  PubMed  CAS  Google Scholar 

  10. Catovsky D, Richards S, Matutes E, et al.: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007, 370:230–239.

    Article  PubMed  CAS  Google Scholar 

  11. Eichhorst BF, Busch R, Hopfinger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885–891.

    Article  PubMed  CAS  Google Scholar 

  12. Dearden C, Wade R, Else M, et al.: The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008, 111:1820–1826.

    Article  PubMed  CAS  Google Scholar 

  13. Boumpas DT, Chrousos GP, Wilder RL, et al.: Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993, 119:1198–1208.

    PubMed  CAS  Google Scholar 

  14. Akpek G, McAneny D, Weintraub L: Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol 1999, 61:98–102.

    Article  PubMed  CAS  Google Scholar 

  15. King KE, Ness PM: Treatment of autoimmune hemolytic anemia. Semin Hematol 2005, 42:131–136.

    Article  PubMed  CAS  Google Scholar 

  16. Keating MJ, O’Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079–4088.

    Article  PubMed  CAS  Google Scholar 

  17. Tam CS, O’Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975–980.

    Article  PubMed  CAS  Google Scholar 

  18. Coiffier B, Lepretre S, Pedersen LM, et al.: Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 study. Blood 2008, 111:1094–1100.

    Article  PubMed  CAS  Google Scholar 

  19. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002, 99:3554–3561.

    Article  PubMed  CAS  Google Scholar 

  20. Hillmen P, Skotnicki AB, Robak T, et al.: Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616–5623.

    Article  PubMed  CAS  Google Scholar 

  21. D’Arena G, Taylor RP, Cascavilla N, Lindorfer MA: Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia? Endocr Metab Immune Disord Drug Targets 2008, 8:62–68.

    Article  PubMed  CAS  Google Scholar 

  22. Hegde UP, Wilson WH, White T, Cheson BD: Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002, 100:2260–2262.

    PubMed  CAS  Google Scholar 

  23. Zaja F, Vianelli N, Sperotto A, et al.: Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003, 44:1951–1955.

    Article  PubMed  CAS  Google Scholar 

  24. D’Arena G, Laurenti L, Capalbo S, et al.: Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol 2006, 81:598–602.

    Article  PubMed  CAS  Google Scholar 

  25. Narat S, Gandla J, Hoffbrand AV, et al.: Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 2005, 90:1273–1274.

    PubMed  CAS  Google Scholar 

  26. Gupta N, Kavuru S, Patel D, et al.: Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002, 16:2092–2095.

    Article  PubMed  CAS  Google Scholar 

  27. Zaja F, Battista ML, Pirrotta MT, et al.: Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 2008, 93:930–933.

    Article  PubMed  CAS  Google Scholar 

  28. Lundin J, Porwit-MacDonald A, Rossmann ED, et al.: Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004, 18:484–490.

    Article  PubMed  CAS  Google Scholar 

  29. Rodon P, Breton P, Courouble G: Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol 2003, 70:319–321.

    Article  PubMed  Google Scholar 

  30. Lundin J, Karlsson C, Celsing F: Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol 2006, 23:137–139.

    Article  PubMed  Google Scholar 

  31. Royer B, Vaida I, Etienne A, et al.: Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab. Leukemia 2007, 21:1841–1842.

    Article  PubMed  CAS  Google Scholar 

  32. Karlsson C, Hansson L, Celsing F, Lundin J: Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia 2007, 21:511–514.

    Article  PubMed  CAS  Google Scholar 

  33. Laurenti L, Tarnani M, Efremov DG, et al.: Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia 2007, 21:1819–1821.

    Article  PubMed  CAS  Google Scholar 

  34. Ammatuna E, Marino C, Mitra ME, et al.: Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab. Eur J Haematol 2004, 73:225–226.

    Article  PubMed  CAS  Google Scholar 

  35. Rezvany MR, Tehrani MJ, Karlsson C, et al.: Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2006, 135:475–485.

    Article  PubMed  CAS  Google Scholar 

  36. Kiaii S, Choudhury A, Mozaffari F, et al.: Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment. Leuk Lymphoma 2006, 47:1229–1238.

    Article  PubMed  CAS  Google Scholar 

  37. Otton SH, Turner DL, Frewin R, et al.: Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. Br J Haematol 1999, 106:261–262.

    Article  PubMed  CAS  Google Scholar 

  38. Lundin J, Kimby E, Bjökholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768–773.

    Article  PubMed  CAS  Google Scholar 

  39. D’Arena G, de Filippi R, Pinto A: DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab. Leuk Lymphoma 2007, 48:625–627.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Karolinska University Hospital Solna, SE-171 76, Stockholm, Sweden

    Anders Österborg

Authors
  1. Anders Österborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claes Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeanette Lundin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anders Österborg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Österborg, A., Karlsson, C. & Lundin, J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep 4, 47–53 (2009). https://doi.org/10.1007/s11899-009-0007-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-009-0007-4

Keywords

Search

Navigation